Overview

Morphogenesis, Inc. and CohBar, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

The companies hosted a joint webcast on May 23, 2023, to discuss the transaction.

CohBar Website

Access Webcast Replay

We Put Patients First

We’d like to express our appreciation for the patients who participate in our clinical trials. Your contributions will help our efforts to treat and cure cancer.

Advanced Merkel Cell Carcinoma (MCC)

Advanced Merkel Cell Carcinoma is an aggressive, rare neuroendocrine tumor of the skin. It has a high frequency of locoregional recurrence and metastasis, and a high mortality rate. Approximately 45%-50% of patients have primary resistance to the current standard of care, first line pembrolizumab.1

MCC has an incidence rate of approximately 2,500 people per year and it is expected to increase by 30% by 2025.2

Patient Resources:

Skin Cancer Foundation MerckellCell.Org Memorial Sloan Kettering Cancer Center

1 N Engl J Med 2016; 374:2542-2552 DOI: 10.1056/NEJMoa1603702

2 Paulson KG, Park SY, Vandeven NA, et al. Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics. J Am Acad Dermatol. 2018;78(3):457-463.e2. doi:10.1016/j.jaad.2017.10.028

Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse large B-cell lymphoma is an aggressive form of non-Hodgkin lymphoma that affects B-lymphocytes. Lymphocytes are a type of white blood cell that make antibodies to fight infections and are an important part of the lymphatic system. DLBCL makes up about 30% of all lymphomas and affects about 7 out of every 100,000 people each year.1

Patient Resources:

Lymphoma Research Foundation Leukemia & Lymphoma Society® DLBCL Support Source Cancer Support Community

1 N Engl J Med 2016; 374:2542-2552 DOI: 10.1056/NEJMoa1603702

Myelodysplasia Syndrome (MDS)

Myelodysplastic syndromes are conditions that can occur when the blood-forming cells in the bone marrow become abnormal. This leads to low numbers of one or more types of blood cells. Approximately 15,000 to 20,000 people are diagnosed with MDS in the United States each year.1

Patient Resources:

MDS Foundation AAMDS

1 https://www.mskcc.org/cancer-care/types/myelodysplastic-syndrome?pn_mapping=pn_11

Acute Myeloid Leukemia (AML)

Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes a large number of abnormal blood cells. It can affect red and white blood cells and platelets. AML is one of the most common types of leukemia in adults with approximately 20,000 people diagnosed each year.1

Patient Resources:

Leukemia and Lymphoma Foundation Cancer Support Community KnowAML.com

1 https://www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html#:~:text=AML%20is%20one%20of%20the,with%20AML%20is%20about%2068.

These links are meant for informational purposes only and are not meant to replace medical advice.